Tag Archive for: Appointment

Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types

/in

Dr. Aleix Prat, an internationally recognized leader in drug and biomarker development appointed Chair of the Advisory Board Dr. Jutta Amersdorffer appointed as Chief Medical Officer and Stéphane Durant des Aulnois appointed as Chief Financial Officer Accelerating development of first-in-class ADCs in multiple large solid tumor types designed against novel targets with a focus on […]

Read more

LoQus23 Therapeutics appoints Cyrus Mozayeni MD to Chair of the Board of Directors

/in

Dr Mozayeni brings deep experience in biotech corporate strategy and business development Appointment follows successful £35 million Series A fundraise at the end of 2024 to take its MSH3 inhibitors to treat Huntington’s disease into the clinic Cambridge, UK, 18 February 2025 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that […]

Read more

Outrun Therapeutics expands leadership team with appointment of Matthew Fyfe as Chief Scientific Officer

/in

Brings extensive small molecule drug discovery, development, and clinical experience across multiple therapeutic areas Will drive application of Outrun’s novel, proprietary X-E3L platform for protein stabiliser discovery to develop a pipeline of high-quality drug candidates targeting E3 ligases Continues strong momentum following 2024 emergence from stealth with $10M seed financing Dundee, Scotland – 13 January […]

Read more

Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of Directors

/in

Former senior vice president of antibody research at Genmab who has co-invented numerous FDA-approved therapeutic antibodies and as well as its DuoBody® bi-specific antibody platform. Brings decades of experience in developing strong pipelines of antibody-based drugs from platforms, growing scientific teams and managing partnerships with Pharma companies Appointment comes as Commit looks to progress towards […]

Read more

Experienced Industry Leader Dr. Joerg Moeller Appointed as Chief Executive Officer of Antag Therapeutics

/in

Former Head of Global R&D at Bayer AG and an exceptional leader with a wealth of experience across biopharma Pivotal time of transition as the company prepares to start clinical development of its first-in-class lead candidate, AT-7687 in obesity AT-7687 offers a new mechanism of action, to set a new standard in obesity management Copenhagen, […]

Read more
© Optimum Strategic Communications.